CLVS Clovis Oncology Inc.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. It also provides lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/Ã), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3); and FAP-2286, a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. The company distributes its products primarily through specialty pharmacies and distributors to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, and Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. The company was incorporated in 2009 and is headquartered in Boulder, Colorado.

Date	Price Target	Rating	Analyst
5/6/2022		Buy → Neutral	H.C. Wainwright
9/21/2021	$10.00 → $9.00	Buy	HC Wainwright & Co.
8/5/2021	$12.00 → $10.00	Buy	HC Wainwright & Co.

Clovis Oncology Inc.

Peers

Recent Analyst Ratings for Clovis Oncology Inc.

Clovis Oncology Inc. SEC Filings

SEC Form EFFECT filed by Clovis Oncology Inc.

SEC Form 15-12G filed by Clovis Oncology Inc.

SEC Form S-8 POS filed by Clovis Oncology Inc.

SEC Form S-8 POS filed by Clovis Oncology Inc.

SEC Form S-8 POS filed by Clovis Oncology Inc.

SEC Form S-8 POS filed by Clovis Oncology Inc.

SEC Form S-8 POS filed by Clovis Oncology Inc.

SEC Form S-8 POS filed by Clovis Oncology Inc.

SEC Form S-8 POS filed by Clovis Oncology Inc.

SEC Form S-8 POS filed by Clovis Oncology Inc.

Clovis Oncology Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Rolfe Lindsey converted options into 8,374 shares and sold $4,188 worth of shares (4,261 units at $0.98), increasing direct ownership by 4% to 113,691 units (tax withholding)

SEC Form 4: Gross Paul Edward converted options into 10,248 shares and sold $4,649 worth of shares (4,730 units at $0.98), increasing direct ownership by 6% to 98,330 units (for tax liability)

SEC Form 4: Muehl Daniel W converted options into 10,248 shares and sold $4,501 worth of shares (4,579 units at $0.98), increasing direct ownership by 6% to 104,830 units to cover withholding tax

SEC Form 4: Harding Thomas C. sold $1,736 worth of shares (1,766 units at $0.98) and converted options into 3,555 shares, increasing direct ownership by 9% to 19,487 units to satisfy tax liability

SEC Form 4: Ivers-Read Gillian C converted options into 8,374 shares and sold $3,618 worth of shares (3,681 units at $0.98), increasing direct ownership by 2% to 293,612 units to satisfy withholding obligation

SEC Form 4: Harding Thomas C. converted options into 15 shares and sold $8 worth of shares (6 units at $1.29) (withholding obligation)

SEC Form 4: Gross Paul Edward converted options into 5,063 shares and sold $2,770 worth of shares (2,308 units at $1.20), increasing direct ownership by 3% to 92,812 units to satisfy tax liability

SEC Form 4: Harding Thomas C. sold $1,939 worth of shares (1,616 units at $1.20) and converted options into 3,404 shares, increasing direct ownership by 9% to 17,816 units to satisfy withholding obligation

SEC Form 4: Rolfe Lindsey converted options into 5,063 shares and sold $3,054 worth of shares (2,545 units at $1.20), increasing direct ownership by 2% to 109,578 units to satisfy withholding tax

SEC Form 4: Muehl Daniel W converted options into 5,063 shares and sold $2,681 worth of shares (2,234 units at $1.20), increasing direct ownership by 3% to 99,161 units (tax withholding)